Annals of Oncology Journal Club

Questions discussed in this category

With the recent FDA approval of adjuvant ribociclib, what factors do you use to decide between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?

7 Answers available

Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?

5 Answers available

Papers discussed in this category

Annals of Oncology, 2021 Sep 29

Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.

European journal of cancer (Oxford, England : 1990), 2024 Jun 28

CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

The New England journal of medicine, 2024 Mar 21

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Dec 31

TRADE: A phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025 Sep 17

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Related Topics